In people with ocular myasthenia gravis (OMG), disease onset during adulthood, the presence of nerve abnormalities, anti-acetylcholine receptor (AChR)…
Marta Figueiredo, PhD
Editorial Associate Director of Resource Pages
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology, and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — those that make up the lining of blood vessels — found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. She has also authored several research papers published in peer-reviewed international scientific journals. Joana joined Bionews in 2018, starting as a science writer, then moving to a science editor position in 2020, and to editorial associate director of resource pages in 2025.
Education
- PhD, Biomedical Sciences, specialty of Molecular and Cellular Biology
- MSc, Evolutionary and Developmental Biology
- BSc, Biology, speciality Evolutionary and Developmental Biology
Certifications
- ICH Good Clinical Practice E6 (R2)
Published Works
- Non-canonical Wnt signaling regulates junctional mechanocoupling during angiogenic collective cell migration. eLife · 2019
- YAP and TAZ regulate adherens junction dynamics and endothelial cell distribution during vascular development. eLife · 2018
- Endothelial cell dynamics in vascular remodelling. Clinical Hemorheology and Microcirculation · 2016
Professional Accomplishments
- Awarded 2 Erasmus scholarships, several research fellowships, a scholarship conference award, and an honorable mention.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marta Figueiredo, PhD
For the first time, a genetic risk factor for myasthenia gravis (MG) has been identified that involves a gene — AGRN…
The European Medicines Agency (EMA) has agreed to review Argenx’s application requesting the approval of its lead candidate,…
Harbour BioMed’s investigational therapy batoclimab (HBM9161) safely and rapidly eases symptoms and lowers the levels of harmful antibodies in…
Women with myasthenia gravis (MG) given standard treatment improve significantly less in both objective and patient-reported outcome measures than…
Most generalized myasthenia gravis (gMG) patients respond to Soliris (eculizumab) within three months of treatment, but some have to wait…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
Editor’s note: The Myasthenia Gravis News team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…
Blood levels of two pro-inflammatory subsets of immune T-cells are abnormally low in people with myasthenia gravis (MG) who…